Stifel Nicolaus reiterated their hold rating on shares of Colgate-Palmolive (NYSE:CL) in a research note released on Wednesday. Stifel Nicolaus currently has a $75.00 price objective on the stock.
Several other equities research analysts have also issued reports on CL. Macquarie raised Colgate-Palmolive from a neutral rating to an outperform rating and set a $81.00 price objective for the company in a research note on Tuesday, December 19th. Zacks Investment Research lowered Colgate-Palmolive from a hold rating to a sell rating in a research note on Tuesday, December 19th. Jefferies Group reaffirmed a hold rating and issued a $79.00 price objective on shares of Colgate-Palmolive in a research note on Friday, January 26th. BNP Paribas lowered Colgate-Palmolive from an outperform rating to an underperform rating in a research note on Tuesday, January 30th. Finally, Citigroup raised their price objective on Colgate-Palmolive from $75.00 to $80.00 and gave the company a neutral rating in a research note on Tuesday, January 30th. Three analysts have rated the stock with a sell rating, eleven have given a hold rating and four have assigned a buy rating to the company’s stock. Colgate-Palmolive currently has an average rating of Hold and an average target price of $77.91.
NYSE CL opened at $72.08 on Wednesday. The company has a market cap of $63,224.85, a price-to-earnings ratio of 25.17, a PEG ratio of 2.72 and a beta of 0.74. The company has a debt-to-equity ratio of 27.02, a current ratio of 1.36 and a quick ratio of 1.00. Colgate-Palmolive has a 1-year low of $67.86 and a 1-year high of $77.91.
Colgate-Palmolive (NYSE:CL) last posted its quarterly earnings data on Friday, January 26th. The company reported $0.75 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.75. The business had revenue of $3.89 billion during the quarter, compared to analyst estimates of $3.92 billion. Colgate-Palmolive had a return on equity of 1,716.69% and a net margin of 13.10%. The company’s revenue for the quarter was up 4.6% on a year-over-year basis. During the same period last year, the company earned $0.75 EPS. research analysts forecast that Colgate-Palmolive will post 3.18 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, May 15th. Investors of record on Friday, April 20th will be paid a dividend of $0.42 per share. This is a positive change from Colgate-Palmolive’s previous quarterly dividend of $0.40. This represents a $1.68 dividend on an annualized basis and a dividend yield of 2.33%. The ex-dividend date is Thursday, April 19th. Colgate-Palmolive’s dividend payout ratio (DPR) is currently 55.75%.
In related news, insider Daniel B. Marsili sold 5,692 shares of the firm’s stock in a transaction that occurred on Wednesday, February 21st. The stock was sold at an average price of $70.19, for a total transaction of $399,521.48. Following the completion of the sale, the insider now directly owns 41,677 shares of the company’s stock, valued at approximately $2,925,308.63. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CTO Patricia Verduin sold 1,572 shares of the firm’s stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $70.17, for a total value of $110,307.24. Following the sale, the chief technology officer now directly owns 50,675 shares of the company’s stock, valued at $3,555,864.75. The disclosure for this sale can be found here. Insiders have sold a total of 474,305 shares of company stock valued at $33,776,113 over the last three months. 1.02% of the stock is owned by corporate insiders.
Hedge funds have recently modified their holdings of the stock. Virtue Capital Management LLC bought a new stake in shares of Colgate-Palmolive during the 4th quarter worth approximately $104,000. Jacobi Capital Management LLC raised its position in Colgate-Palmolive by 125.5% during the 3rd quarter. Jacobi Capital Management LLC now owns 1,443 shares of the company’s stock valued at $104,000 after purchasing an additional 803 shares in the last quarter. Calton & Associates Inc. bought a new stake in Colgate-Palmolive during the 4th quarter valued at $126,000. Cerebellum GP LLC bought a new stake in Colgate-Palmolive during the 4th quarter valued at $129,000. Finally, Trustcore Financial Services LLC bought a new stake in Colgate-Palmolive during the 4th quarter valued at $140,000. 73.64% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: This piece was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another site, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/04/19/colgate-palmolives-cl-hold-rating-reaffirmed-at-stifel-nicolaus.html.
Colgate-Palmolive Company (Colgate) is a consumer products company. The Company operates in two product segments: Oral, Personal and Home Care, and Pet Nutrition. The Oral, Personal and Home Care product segment is operated through five geographic segments, which include North America, Latin America, Europe, Asia Pacific and Africa/Eurasia.
Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with MarketBeat.com's FREE daily email newsletter.